News | US funding freeze puts malaria control and genomics research at risk
On June 1, 2025, SciDev.Net reported that the US funding freeze had a “catastrophic” impact on malaria-control programs in Africa. Jane Carlton, director of the Johns Hopkins Malaria Research Institute, said in an interview that the freeze threatens control efforts and could impede malaria genomics research. The US President’s Malaria Initiative (PMI) was among several US Agency for International Development (USAID)-supported programs affected by Trump administration reforms, with funding cut this year.
Malaria-control programs face severe challenges
PMI was a five-year program designed to help 15 African countries control malaria, but the US funding freeze led to its termination. Carlton said models predict that fully dismantling it would result in 18 million additional cases and 160,000 deaths each year.
Clinics in Uganda have begun rationing rapid diagnostic tests, and PMI offices in Ethiopia stopped distributing mosquito nets midway through the program. Artemisinin-based antimalarial medicines are also in short supply, with five African countries holding less than three months of stock. Beyond the public-health crisis, malaria costs Africa’s economy about US$12 billion annually.
Why should the US continue funding malaria control?
Carlton said malaria control is important even for high-income countries. First, malaria is not solely another country’s problem. Although US cases are mainly imported by travelers, Anopheles mosquitoes remain present in states such as Florida and Texas. Second, the US eliminated malaria in the 1950s through drainage and DDT, creating a moral responsibility to share that knowledge and support global control. Finally, stable, healthy populations can reduce conflict, strengthen social resilience, and support national security.
Genomics research faces a funding bottleneck
Carlton said malaria genomics has made major advances over the past two decades. Researchers mapped the malaria parasite genome in the early 2000s, laying a foundation for drug development. Scientists now combine parasite, human, and mosquito genomic data to track drug resistance and outbreaks.
This work depends on sustained funding. Carlton emphasized that genomics is a foundational tool for precision medicine, but translating genetic discoveries into medicines requires extensive international cooperation. Without funding, even the most advanced technologies will stall.
How is artificial intelligence changing malaria research?
Carlton identified three main uses of artificial intelligence (AI) in malaria research:
Outbreak prediction: machine-learning models analyze climate data, population movement, and historical trends to predict outbreaks and help deploy mosquito nets and other protective measures in advance.
AI-assisted diagnosis: algorithms analyze blood smears to detect parasites and reduce human error, although dust on microscopes, poor lighting, and other environmental factors can affect real-world results.
Protein-structure prediction: AI tools such as AlphaFold can predict the three-dimensional structure of malaria-parasite proteins within hours, helping drug developers design treatments targeting those proteins more efficiently.
AI use in malaria research also raises ethical concerns, especially the risk of data bias. Most genomic data come from Africa, but AI models are often trained in Western laboratories and may overlook regional differences, such as behavioral differences between urban and rural African mosquito species.
Innovation and challenges in malaria-control research
One innovation that most interests Carlton is an environmentally friendly bacterial granule that kills mosquito larvae without chemicals. It is inexpensive, environmentally friendly, and can be produced locally. Gene-drive mosquitoes are also receiving attention. These mosquitoes are modified to prevent malaria-parasite transmission or reduce mosquito fertility, and early trials in Burkina Faso have shown preliminary results. Public acceptance, however, remains a challenge.
Conclusion: urgent action is needed to prevent setbacks
Despite funding freezes and other challenges, Carlton remains hopeful about malaria elimination. Many African countries are increasing investment; Nigeria recently allocated US$200 million to health to offset reduced US funding. With vaccines, gene-editing technology, and lessons from successful efforts in countries such as India and Egypt, malaria could be eliminated globally within decades. Carlton warned, however, that slowing down now would undo decades of progress.
News | US funding freeze puts malaria control and genomics research at risk
News | US funding freeze puts malaria control and genomics research at risk
On June 1, 2025, SciDev.Net reported that the US funding freeze had a “catastrophic” impact on malaria-control programs in Africa. Jane Carlton, director of the Johns Hopkins Malaria Research Institute, said in an interview that the freeze threatens control efforts and could impede malaria genomics research. The US President’s Malaria Initiative (PMI) was among several US Agency for International Development (USAID)-supported programs affected by Trump administration reforms, with funding cut this year.
Malaria-control programs face severe challenges
PMI was a five-year program designed to help 15 African countries control malaria, but the US funding freeze led to its termination. Carlton said models predict that fully dismantling it would result in 18 million additional cases and 160,000 deaths each year.
Clinics in Uganda have begun rationing rapid diagnostic tests, and PMI offices in Ethiopia stopped distributing mosquito nets midway through the program. Artemisinin-based antimalarial medicines are also in short supply, with five African countries holding less than three months of stock. Beyond the public-health crisis, malaria costs Africa’s economy about US$12 billion annually.
Why should the US continue funding malaria control?
Carlton said malaria control is important even for high-income countries. First, malaria is not solely another country’s problem. Although US cases are mainly imported by travelers, Anopheles mosquitoes remain present in states such as Florida and Texas. Second, the US eliminated malaria in the 1950s through drainage and DDT, creating a moral responsibility to share that knowledge and support global control. Finally, stable, healthy populations can reduce conflict, strengthen social resilience, and support national security.
Genomics research faces a funding bottleneck
Carlton said malaria genomics has made major advances over the past two decades. Researchers mapped the malaria parasite genome in the early 2000s, laying a foundation for drug development. Scientists now combine parasite, human, and mosquito genomic data to track drug resistance and outbreaks.
This work depends on sustained funding. Carlton emphasized that genomics is a foundational tool for precision medicine, but translating genetic discoveries into medicines requires extensive international cooperation. Without funding, even the most advanced technologies will stall.
How is artificial intelligence changing malaria research?
Carlton identified three main uses of artificial intelligence (AI) in malaria research:
Outbreak prediction: machine-learning models analyze climate data, population movement, and historical trends to predict outbreaks and help deploy mosquito nets and other protective measures in advance.
AI-assisted diagnosis: algorithms analyze blood smears to detect parasites and reduce human error, although dust on microscopes, poor lighting, and other environmental factors can affect real-world results.
Protein-structure prediction: AI tools such as AlphaFold can predict the three-dimensional structure of malaria-parasite proteins within hours, helping drug developers design treatments targeting those proteins more efficiently.
AI use in malaria research also raises ethical concerns, especially the risk of data bias. Most genomic data come from Africa, but AI models are often trained in Western laboratories and may overlook regional differences, such as behavioral differences between urban and rural African mosquito species.
Innovation and challenges in malaria-control research
One innovation that most interests Carlton is an environmentally friendly bacterial granule that kills mosquito larvae without chemicals. It is inexpensive, environmentally friendly, and can be produced locally. Gene-drive mosquitoes are also receiving attention. These mosquitoes are modified to prevent malaria-parasite transmission or reduce mosquito fertility, and early trials in Burkina Faso have shown preliminary results. Public acceptance, however, remains a challenge.
Conclusion: urgent action is needed to prevent setbacks
Despite funding freezes and other challenges, Carlton remains hopeful about malaria elimination. Many African countries are increasing investment; Nigeria recently allocated US$200 million to health to offset reduced US funding. With vaccines, gene-editing technology, and lessons from successful efforts in countries such as India and Egypt, malaria could be eliminated globally within decades. Carlton warned, however, that slowing down now would undo decades of progress.
Story source:
Collected online